Overview

The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
Phase:
Phase 4
Details
Lead Sponsor:
Centocor Ortho Biotech Services, L.L.C.
Treatments:
Infliximab
Methotrexate